# Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

> **NCT00998296** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT00998296
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-12
- **Final completion:** 2014-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00998296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00998296, "Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00998296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*